+

WO2003035904A3 - Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps - Google Patents

Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps Download PDF

Info

Publication number
WO2003035904A3
WO2003035904A3 PCT/EP2002/011397 EP0211397W WO03035904A3 WO 2003035904 A3 WO2003035904 A3 WO 2003035904A3 EP 0211397 W EP0211397 W EP 0211397W WO 03035904 A3 WO03035904 A3 WO 03035904A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
antibody treatment
treatment response
response
Prior art date
Application number
PCT/EP2002/011397
Other languages
English (en)
Other versions
WO2003035904A2 (fr
Inventor
Herve Watier
Guillaume Cartron
Philippe Colombat
Original Assignee
Chru Tours
Innate Pharma
Herve Watier
Guillaume Cartron
Philippe Colombat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003035904(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE2002782887 priority Critical patent/DE02782887T1/de
Priority to EP02782887A priority patent/EP1436427B1/fr
Priority to AU2002346999A priority patent/AU2002346999B2/en
Priority to JP2003538404A priority patent/JP4216720B2/ja
Priority to CA2463746A priority patent/CA2463746C/fr
Application filed by Chru Tours, Innate Pharma, Herve Watier, Guillaume Cartron, Philippe Colombat filed Critical Chru Tours
Priority to DK02782887T priority patent/DK1436427T3/da
Priority to US10/492,183 priority patent/US7858300B2/en
Priority to DE60228108T priority patent/DE60228108D1/de
Publication of WO2003035904A2 publication Critical patent/WO2003035904A2/fr
Publication of WO2003035904A3 publication Critical patent/WO2003035904A3/fr
Priority to US12/858,343 priority patent/US20110123996A1/en
Priority to US14/142,175 priority patent/US20150017633A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant l'évaluation ou l'estimation de la réponse d'un sujet à un traitement thérapeutique particulier. L'invention porte notamment sur des méthodes de détermination de la réponse de sujets, ou d'adaptation du protocole de traitement de sujets traités avec des anticorps thérapeutiques. L'invention est basée sur la détermination du génotype FCGR3A d'un sujet. Elle peut être utilisée pour des patients souffrant de tumeurs malignes, notamment de lymphome, et convient à la sélection des meilleurs sujets répondants et/ou à l'ajustement de condition de traitement ou de protocole pour les sujets répondants à profil de réponse faible.
PCT/EP2002/011397 2001-10-19 2002-10-11 Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps WO2003035904A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE60228108T DE60228108D1 (de) 2001-10-19 2002-10-11 Methoden und kompositionen zur bewertung von antikörper behandlungen
EP02782887A EP1436427B1 (fr) 2001-10-19 2002-10-11 Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
AU2002346999A AU2002346999B2 (en) 2001-10-19 2002-10-11 Methods and compositions to evaluate antibody treatment response
JP2003538404A JP4216720B2 (ja) 2001-10-19 2002-10-11 抗体処置応答を評価するための方法および組成物
CA2463746A CA2463746C (fr) 2001-10-19 2002-10-11 Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
DE2002782887 DE02782887T1 (de) 2001-10-19 2002-10-11 Methoden und kompositionen, antikörper behandlung zu bewerten
DK02782887T DK1436427T3 (da) 2001-10-19 2002-10-11 Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
US10/492,183 US7858300B2 (en) 2001-10-19 2002-10-11 Methods and compositions to evaluate antibody treatment response
US12/858,343 US20110123996A1 (en) 2001-10-19 2010-08-17 Methods and compositions to evaluate antibody treatment response
US14/142,175 US20150017633A1 (en) 2001-10-19 2013-12-27 Methods and compositions to evaluate antibody treatment response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402718.9 2001-10-19
EP01402718 2001-10-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/492,183 A-371-Of-International US7858300B2 (en) 2001-10-19 2002-10-11 Methods and compositions to evaluate antibody treatment response
US12/858,343 Continuation US20110123996A1 (en) 2001-10-19 2010-08-17 Methods and compositions to evaluate antibody treatment response

Publications (2)

Publication Number Publication Date
WO2003035904A2 WO2003035904A2 (fr) 2003-05-01
WO2003035904A3 true WO2003035904A3 (fr) 2003-10-16

Family

ID=8182931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011397 WO2003035904A2 (fr) 2001-10-19 2002-10-11 Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps

Country Status (11)

Country Link
US (3) US7858300B2 (fr)
EP (1) EP1436427B1 (fr)
JP (1) JP4216720B2 (fr)
CN (1) CN1329524C (fr)
AT (1) ATE403750T1 (fr)
AU (1) AU2002346999B2 (fr)
CA (1) CA2463746C (fr)
DE (2) DE02782887T1 (fr)
DK (1) DK1436427T3 (fr)
ES (1) ES2311634T3 (fr)
WO (1) WO2003035904A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE403750T1 (de) * 2001-10-19 2008-08-15 Chru Tours Methoden und kompositionen zur bewertung von antikörper behandlungen
EP2385139A1 (fr) * 2002-07-31 2011-11-09 University of Southern California Polymorphismes pour prédire les maladies les résultats de traitements
KR101299599B1 (ko) 2003-07-24 2013-08-23 위니베르시따 데글리 스뚜디 디 뻬루지아 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물
GB0324778D0 (en) * 2003-10-23 2003-11-26 Forinnova As Method
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
BRPI0418722A (pt) * 2004-04-07 2007-09-11 Chiron Corp ensaios baseados em ácidos nucléicos para identificação de polimorfismos do receptor fc
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法
WO2005123947A1 (fr) * 2004-06-15 2005-12-29 Universite Francois Rabelais Procede d'evaluation de la susceptibilite a la thrombocytopenie medicamenteuse
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
AU2005267148A1 (en) * 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
RU2442605C2 (ru) 2005-11-01 2012-02-20 Новартис Аг Применения антител против cd40
AU2006308860B2 (en) * 2005-11-01 2012-01-12 Novartis Ag Uses of anti-CD40 antibodies
CA2631630A1 (fr) * 2005-11-30 2007-06-07 University Of Southern California Polymorphismes de fc-gamma destines a predire une maladie et l'issue d 'un traitement
US8592149B2 (en) * 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
US20100092485A1 (en) * 2007-01-18 2010-04-15 University Of Southern California Genetic Markers for Predicting Responsiveness to Combination Therapy
US20090142763A1 (en) * 2007-08-22 2009-06-04 Wyeth Nested pcr-based method for specific genotyping of the fc gamma receptor iiia gene
US20120070432A1 (en) * 2009-05-28 2012-03-22 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
EP2383572A1 (fr) * 2010-04-28 2011-11-02 Assistance Publique Hôpitaux de Marseille Test de l'activité humorale cellulaire (CHAT)
RU2441023C1 (ru) * 2010-07-15 2012-01-27 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
FR3037340A1 (fr) 2015-06-09 2016-12-16 Univ Montpellier Methode de pronostic d'hemopathies lymphoides
ES2905536T3 (es) * 2015-10-02 2022-04-11 Momenta Pharmaceuticals Inc Procedimientos terapéuticos y de diagnóstico para enfermedades autoinmunes y/o inflamación
US10226088B1 (en) * 2017-03-30 2019-03-12 Robert Russell Pet waste disposable glove
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
CN108676875B (zh) * 2018-04-10 2022-01-18 哈尔滨医科大学 Cd20、fcgriia及fcgriiia基因在弥漫大b细胞淋巴瘤预后中的用途
EP3911340A4 (fr) * 2019-01-18 2022-11-16 Acepodia Biotechnologies Ltd. <sup2/>? <sub2/>?+? ?nouvelle cellule tueuse naturelle cd16et procédé de culture de cellule tueuse naturelle cd16 <ns2:sup>+</ns2:sup>
TW202146644A (zh) * 2020-01-16 2021-12-16 育世博生物科技股份有限公司 一種新穎的ｃｄ１６陽性自然殺手細胞及一種培養ｃｄ１６陽性自然殺手細胞的方法
CN114277149B (zh) * 2021-12-30 2023-09-22 苏州方科生物科技有限公司 一种检测cd16a基因多态性的试剂盒及其应用和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012848A2 (fr) * 1999-08-14 2001-02-22 University Of Leeds Marqueur genetique de la polyarthrite rhumatoide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446314A (en) * 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Fractionation of heparin
JP2657221B2 (ja) * 1988-05-27 1997-09-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ヒトＦｃγレセプター▲ＩＩＩ▼
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5552526A (en) * 1993-05-14 1996-09-03 Cancer Institute MDC proteins and DNAS encoding the same
US5830652A (en) * 1994-08-30 1998-11-03 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for determining predisposition to severe forms of autoimmune disease by determining Fcy receptor allelic patterns
US5866337A (en) * 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
CA2257197A1 (fr) * 1996-06-03 1997-12-11 Jeffrey Edberg Polymorphisme du recepteur fc
DE69709493T2 (de) * 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
US20020076702A1 (en) * 2000-02-17 2002-06-20 Rakesh Anand Methods
ATE403750T1 (de) 2001-10-19 2008-08-15 Chru Tours Methoden und kompositionen zur bewertung von antikörper behandlungen
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
WO2005123947A1 (fr) * 2004-06-15 2005-12-29 Universite Francois Rabelais Procede d'evaluation de la susceptibilite a la thrombocytopenie medicamenteuse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012848A2 (fr) * 1999-08-14 2001-02-22 University Of Leeds Marqueur genetique de la polyarthrite rhumatoide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALTZ R ET AL: "ASSOCIATION OF FCGAMMA RIIIA-158F ALLELE WITH RHEUMATOID ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 42, September 1999 (1999-09-01), pages S245, XP000990708, ISSN: 0004-3591 *
COLOMBAT: "Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: clinical and molecular evaluation", BLOOD, vol. 97, pages 101 - 106, XP002201492 *
LEPPERS-VAN DE STRAAT F G J ET AL: "A novel PCR-based method for direct Fcgamma receptor IIIa (CD16) allotyping", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 242, no. 1-2, 28 August 2000 (2000-08-28), pages 127 - 132, XP004210716, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
CA2463746A1 (fr) 2003-05-01
US20050064417A1 (en) 2005-03-24
JP2005506093A (ja) 2005-03-03
DK1436427T3 (da) 2008-12-08
US20150017633A1 (en) 2015-01-15
EP1436427A2 (fr) 2004-07-14
EP1436427B1 (fr) 2008-08-06
US7858300B2 (en) 2010-12-28
AU2002346999B2 (en) 2007-11-08
ATE403750T1 (de) 2008-08-15
DE60228108D1 (de) 2008-09-18
CA2463746C (fr) 2014-09-02
CN1329524C (zh) 2007-08-01
CN1571850A (zh) 2005-01-26
JP4216720B2 (ja) 2009-01-28
US20110123996A1 (en) 2011-05-26
DE02782887T1 (de) 2005-01-13
WO2003035904A2 (fr) 2003-05-01
ES2311634T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
WO2003035904A3 (fr) Procedes et compositions pour evaluer la reponse a un traitement a base d&#39;anticorps
WO2004048938A3 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2003039462A3 (fr) Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
WO2004028341A3 (fr) Gene de predisposition pour l&#39;attaque chez l&#39;homme, et procedes de traitement
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003038129A3 (fr) Methodes d&#39;evaluation et de traitement de la leucemie
WO2002098355A3 (fr) Methodes et compositions pour diagnostic et traitement de la resistance a l&#39;insuline et des etats associes
WO2006124866A3 (fr) Dosage immunoenzymetrique ige de serum humain libre
WO2001062784A3 (fr) Proteines
WO2002039122A3 (fr) Compositions et methodes permettant l&#39;identification, l&#39;evaluation, la prevention et la therapie des maladies cardio-vasculaires
WO2003084384A3 (fr) Diagnostic de l&#39;infection a flavivirus
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2002036124A3 (fr) Procede de traitement
WO2003017817A3 (fr) Diagnostic, prevention et traitement du cancer
AU2002365941A1 (en) Methods of diagnosis, monitoring and treatment of fertility
WO2005037231A3 (fr) Methodes de detection et de traitement de la myopathie facioscapulohumerale
WO2005030265A3 (fr) Imagerie optique d&#39;une endometriose
WO2004034994A3 (fr) Procedes et compositions pour determiner les risques de toxicite d&#39;un traitement
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
EP1461351A4 (fr) Methodes et reactifs pour le diagnostic et le traitement du diabete
WO2005023253A8 (fr) Utilisation d&#39;inhibiteurs de pde4 pour le traitement du diabete sucre
WO2006019984A3 (fr) Compositions, procedes et trousses pour le diagnostic et le traitement du syndrome de mort subite du nourrisson
WO2004073499A3 (fr) Diagnostic du glaucome primitif a angle ouvert (gpao)
GB0102408D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002782887

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10492183

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002346999

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2463746

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002820672X

Country of ref document: CN

Ref document number: 2003538404

Country of ref document: JP

Ref document number: 234/MUMNP/2004

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2002782887

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002782887

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载